Authors: LEGROS M DAUPLAT J FLEURY J CURE H SUZANNE F CHASSAGNE J BAY JO SOL C CANIS M CONDAT P CHOUFI B TAVERNIER F GLENAT C CHOLLET P PLAGNE R

Citation: M. Legros et al., HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE IN PATIENTS WITH STAGE-III TO STAGE-IV OVARIAN-CANCER - LONG-TERM RESULTS, Journal of clinical oncology, 15(4), 1997, pp. 1302-1308

Authors: LEGROS M FLEURY J BAY JO CHOUFI B BASILE M CONDAT P GLENAT C COMMUNAL Y TAVERNIER F BONS JM CHOLLET P PLAGNE R CHASSAGNE J

Citation: M. Legros et al., RHGM-CSF VS PLACEBO FOLLOWING RHGM-CSF-MOBILIZED PBPC TRANSPLANTATION- A PHASE-III DOUBLE-BLIND RANDOMIZED TRIAL, Bone marrow transplantation, 19(3), 1997, pp. 209-213

Authors: FLECK SL ROBINSON BL PETERS W THEVIN F BOULARD Y GLENAT C CAILLARD V LANDAU I

Citation: Sl. Fleck et al., THE CHEMOTHERAPY OF RODENT MALARIA .43. FENOZAN B07 (FENOZAN-50F), A DIFLUORINATED 3,3'-SPIROCYCLOPENTANE 1,2,4-TRIOXANE - COMPARISON WITH SOME COMPOUNDS OF THE ARTEMISININ SERIES, Annals of tropical medicine and parasitology, 91(1), 1997, pp. 25-32

Authors: PORTEFAIX G COMMUNAL Y FLEURY J CURE H CHOUFI B FOUASSIER M BONS JM GLENAT C CHOLLET P CHASSAGNE J PLAGNE R LEGROS M

Citation: G. Portefaix et al., INTEREST OF HIGH FLUORESCENCE RETICULOCYTES (HFR)EVALUATION IN OPTIMAL TIME DETERMINATION OF PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) HAVESTING, Blood, 88(10), 1996, pp. 3721-3721